MindBio Therapeutics Corp. (CSE:MBIO)

MindBio Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Selling, General & Admin	0.43	0.63	1.82	2.9
Research & Development	-	-	-	2.46
Operating Expenses	0.43	0.63	3.22	5.4
Operating Income	-1.07	-0.63	-3.22	-5.4
Interest Expense	-0.52	-0.36	-0.45	-0.18
Currency Exchange Gain (Loss)	0.1	-	0.01	-0.11
Other Non Operating Income (Expenses)	0.63	0.58	-0.25	-1.78
EBT Excluding Unusual Items	-0.85	-0.41	-3.92	-7.47
Gain (Loss) on Sale of Investments	-0.01	-0.01	-0.02	-
Other Unusual Items	0.01	0.01	-0.35	-
Pretax Income	-1.64	-0.42	-4.29	-7.47
Net Income	-1.63	-0.42	-4.29	-7.47
Net Income to Common	-1.63	-0.42	-4.29	-7.47
Shares Outstanding (Basic)	121	133	110	53
Shares Outstanding (Diluted)	121	133	110	53
Shares Change (YoY)	-40.06%	20.80%	106.14%	-
EPS (Basic)	-0.01	-0.00	-0.04	-0.14
EPS (Diluted)	-0.01	-0.00	-0.04	-0.14
EBITDA	-	-	-	-5.36
D&A For EBITDA	-	-	-	0.04
EBIT	-1.07	-0.63	-3.22	-5.4

Updated Jan 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.